Qualigen Therapeutics Files 8-K: Security Holder Rights Modified
Ticker: AIXC · Form: 8-K · Filed: Dec 26, 2024 · CIK: 1460702
Sentiment: neutral
Topics: rights-modification, financials
TL;DR
Qualigen modified security holder rights on 12/23/24, filed financials.
AI Summary
Qualigen Therapeutics, Inc. announced on December 23, 2024, a material modification to the rights of its security holders. The company also filed financial statements and exhibits as part of this report. Specific details regarding the modifications and financial information are provided within the filing.
Why It Matters
This filing indicates a significant change in the rights associated with Qualigen's securities, which could impact investors and the company's financial structure.
Risk Assessment
Risk Level: medium — Modifications to security holder rights can introduce uncertainty and potential risks for investors.
Key Players & Entities
- Qualigen Therapeutics, Inc. (company) — Registrant
- December 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 5857 Owens Avenue , Suite 300 , Carlsbad , California 92008 (address) — Principal executive offices
- (760) 452-8111 (phone_number) — Registrant's telephone number
FAQ
What specific material modifications were made to the rights of Qualigen Therapeutics, Inc.'s security holders?
The filing states that there were material modifications to the rights of security holders, but the specific details of these modifications are not provided in the summary information.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 23, 2024.
What is the principal executive office address for Qualigen Therapeutics, Inc.?
The principal executive office is located at 5857 Owens Avenue, Suite 300, Carlsbad, California 92008.
What is the telephone number for Qualigen Therapeutics, Inc.?
The registrant's telephone number is (760) 452-8111.
What is the state of incorporation for Qualigen Therapeutics, Inc.?
Qualigen Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-12-26 16:10:38
Filing Documents
- form8-k.htm (8-K) — 37KB
- ex3-2.htm (EX-3.2) — 143KB
- 0001493152-24-052099.txt ( ) — 382KB
- qlgn-20241223.xsd (EX-101.SCH) — 3KB
- qlgn-20241223_lab.xml (EX-101.LAB) — 33KB
- qlgn-20241223_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. QUALIGEN THERAPEUTICS, INC. Date: December 26, 2024 By: /s/ Kevin Richardson II Kevin Richardson II, Interim Chief Executive Officer